Clinical Trials
42 trialsNCT06880549 2026-05-27
A Study of mRNA-4106 or mRNA-4200 Administered Alone or in Combination With Anti-Cancer Agents in Participants With Solid Tumors
ModernaTX, Inc.
Phase 1 Active not recruiting
NCT05537740 2026-05-20
A First-in-human Study to Learn How Safe the Study Drug BAY3375968, an Anti-CCR8 Antibody, is, When Given Alone or in Combination With Pembrolizumab, How it Affects the Body, How it Moves Into, Through, and Out of the Body, and to Find the Best Dose in Participants With Advanced Solid Tumors
Bayer
Phase 1 Active not recruiting
NCT04337177 2026-05-11
Flavored, Oral Irinotecan VAL-413 (Orotecan®) Given With Temozolomide for Treatment of Recurrent Pediatric Solid Tumors
Valent Technologies, LLC
Phase 1 Active not recruiting
NCT05784441 2026-05-08
A Study of JNJ-90009530 in Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma (r/r B-NHL)
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT05359445 2026-04-30
IMA401 TCER® in Recurrent and/or Refractory Solid Tumors, Alone or in Combination With a Checkpoint Inhibitor
Immatics Biotechnologies GmbH
Phase 1 Active not recruiting
NCT05675449 2026-04-13
MagnetisMM-20
Pfizer
Phase 1 Active not recruiting
NCT06425991 2026-04-13
MajesTEC-10
Janssen Research & Development, LLC
Phase 1 Active not recruiting
NCT03085173 2026-04-07
A Trial of "Armored" CAR T Cells Targeting CD19 For Patients With Relapsed CD19+ Hematologic Malignancies
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT04684108 2026-04-07
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies
Hangzhou Sumgen Biotech Co., Ltd.
Phase 1 Active not recruiting
NCT01822652 2026-04-06
GRAIN
Baylor College of Medicine
Phase 1 Active not recruiting
NCT04279847 2026-04-01
LIMBER
Incyte Corporation
Phase 1 Active not recruiting
NCT05753501 2026-03-27
Study to Evaluate Adverse Events, Change in Disease Activity, and How Oral ABBV-101 Moves Through the Body in Adult Participants With B-Cell Malignancies
AbbVie
Phase 1 Active not recruiting
NCT04756726 2026-03-25
Study to Assess the Safety and Tolerability of CFT7455 in Relapsed/Refractory Non-Hodgkin's Lymphoma or Multiple Myeloma
C4 Therapeutics, Inc.
Phase 1 Active not recruiting
NCT02298348 2026-03-23
N2013-02
New Approaches to Neuroblastoma Therapy Consortium
Phase 1 Active not recruiting
NCT03742245 2026-03-16
Olaparib in Combination With Vorinostat in Patients With Relapsed/Refractory and/or Metastatic Breast Cancer
The Methodist Hospital Research Institute
Phase 1 Active not recruiting
NCT06846606 2026-03-03
Phase 1 Study of AUTX-703 in Relapsed/Refractory AML and MDS
Auron Therapeutics, Inc.
Phase 1 Active not recruiting
NCT05527184 2026-02-20
First in Human Study of IMGN151 in Recurrent Gynaecological Cancers
AbbVie
Phase 1 Active not recruiting
NCT06325748 2026-02-12
SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS
Senti Biosciences
Phase 1 Active not recruiting
NCT04155749 2026-02-11
Study of Anitocabtagene-autoleucel in Participants With Relapsed Refractory Multiple Myeloma
Gilead Sciences
Phase 1 Active not recruiting
NCT04690595 2026-02-11
BAFFR Targeting CAR-T Cells for the Treatment of Relapsed or Refractory B-cell ALL
PeproMene Bio, Inc.
Phase 1 Active not recruiting
NCT02651662 2026-02-02
CLIO-1
Regeneron Pharmaceuticals
Phase 1 Active not recruiting
NCT06359002 2026-01-20
Safety, Pharmacokinetics, and Preliminary Efficacy of BYON4413 in Acute Myeloid Leukemia and Myelodysplastic Neoplasms.
Byondis B.V.
Phase 1 Active not recruiting
NCT06768476 2026-01-16
AML
University of Pennsylvania
Phase 1 Active not recruiting
NCT01562405 2026-01-14
Sotatercept (ACE-011) With Lenalidomide or Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Massachusetts General Hospital
Phase 1 Active not recruiting
NCT01840566 2025-12-03
High Dose Therapy and Autologous Stem Cell Transplantation Followed by Infusion of Chimeric Antigen Receptor (CAR) Modified T-Cells Directed Against CD19+ B-Cells for Relapsed and Refractory Aggressive B Cell Non-Hodgkin Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT02483312 2025-12-01
A Study of (Interleukin-12) IL-12 in Patients With Acute Myelogenous Leukemia (AML)
University Health Network, Toronto
Phase 1 Active not recruiting
NCT05768880 2025-11-20
Study of B7-H3, EGFR806, HER2, And IL13-Zetakine (Quad) CAR T Cell Locoregional Immunotherapy For Pediatric Diffuse Intrinsic Pontine Glioma, Diffuse Midline Glioma, And Recurrent Or Refractory Central Nervous System Tumors
Seattle Children's Hospital
Phase 1 Active not recruiting
NCT05574114 2025-11-04
A Study of Radiation Therapy Before CAR T Cell Therapy for People With B Cell Lymphoma
Memorial Sloan Kettering Cancer Center
Phase 1 Active not recruiting
NCT00368082 2025-10-31
TGF-beta
Baylor College of Medicine
Phase 1 Active not recruiting
NCT05104775 2025-09-26
A Study of GNC-035, a Tetra-specific Antibody, in Participants With Relapsed/Refractory Hematologic Malignancy
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1 Active not recruiting
NCT06381141 2025-09-18
A Study of CLN-619 (Anti-MICA/MICB Antibody) in Patients With Relapsed and Refractory Multiple Myeloma
Cullinan Therapeutics Inc.
Phase 1 Active not recruiting
NCT04608487 2025-07-30
Axi-cel in CNS Lymphoma
Dana-Farber Cancer Institute
Phase 1 Active not recruiting
NCT05617755 2025-07-30
AB-1015, an Integrated Circuit T (ICT) Cell Therapy in Patients With Platinum Resistant Epithelial Ovarian Cancer
Arsenal Biosciences, Inc.
Phase 1 Active not recruiting
NCT06570031 2025-07-02
ONO-4578-06:Phase I Study of ONO-4578 and Letrozole Plus CDK4 /6 Inhibitors in Breast Cancer
Ono Pharmaceutical Co., Ltd.
Phase 1 Active not recruiting
NCT03766126 2025-06-26
Lentivirally Redirected CD123 Autologous T Cells in AML
University of Pennsylvania
Phase 1 Active not recruiting
NCT02332850 2025-05-01
Phase Ib Study of SAR650984 in Combination With Carfilzomib for Treatment of Relapsed or Refractory Multiple Myeloma
University of California, San Francisco
Phase 1 Active not recruiting
NCT05206357 2025-04-08
Study of the Adverse Events and Change in Disease State of Pediatric Participants (and Young Adults Between the Ages of 18-25) With Relapsed/Refractory Aggressive Mature B-cell Neoplasms Receiving Subcutaneous (SC) Injections of Epcoritamab
Genmab
Phase 1 Active not recruiting
NCT04420754 2025-03-30
Study of AIC100 CAR T Cells in Relapsed/Refractory Thyroid Cancer
AffyImmune Therapeutics, Inc.
Phase 1 Active not recruiting
NCT03603951 2024-10-01
A Phase 1 Study of SHR2554 in Subjects With Relapsed or Refractory Mature Lymphoid Neoplasms
Jiangsu HengRui Medicine Co., Ltd.
Phase 1 Active not recruiting
NCT01883297 2024-09-05
"Re-Stimulated" TILs and IL-2 Therapy for Platinum Resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer
University Health Network, Toronto
Phase 1 Active not recruiting
NCT05879744 2024-05-02
A Study of CLN-978 in Patients With Relapsed or Refractory (R/R) B Cell Non-Hodgkin Lymphoma (B-NHL)
Cullinan Therapeutics Inc.
Phase 1 Active not recruiting
NCT04613557 2023-08-31
IMMUNICY-1
Celyad Oncology SA
Phase 1 Active not recruiting